UI Hospitals and Clinics

Clinical Trial Details

Short Title
LY2875358 + Erlotinib & LY2875358 Monotherapy, MET Positive NSCLC w/ Resistance to Erlotinib
Official Title

A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib


The purpose of this study is to test the effectiveness of the research study drugs LY2875358 and erlotinib in making tumors smaller in patients with metastatic non-small cell lung cancer.
This is a research study to test the effectiveness of LY2875358 and erlotinib, also known as "investigational." This means the drug has not been approved by the U.S. Food and Drug Administration (FDA) for the use described in this study. However, the FDA has allowed the use of this drug for research.

About 100 people will be enrolled in the study.

Start Date
April 1, 2014
End Date
August 29, 2014
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Taher Abu Hejleh, MD
Contact Info

Susan Gillen 319-467-5827

Abu Hejleh ; Cancer ; erlotinib therapy ; Lung ; Phase 2 ; Phase ii ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.